Cited 0 times in
An open-label, multicenter, phase II single arm trial of osimertinib in non-small cell lung cancer patients with uncommon EGFR mutation (KCSG-LU15-09)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.